Saby George, MD, FACP, Roswell Park Cancer Institute, explains Update on Checkmate-214 Study | Approval of Nivolumab & Ipilimumab Combination at Annual Meeting 2018
Update on Checkmate-214 Study | Approval of Nivolumab & Ipilimumab Combination
Saby George, MD, FACP, Roswell Park Cancer Institute, explains Update on Checkmate-214 Study | Approval of Nivolumab & Ipilimumab Combination at Annual Meeting 2018